KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into...
DRG Epidemiology’s coverage of glioma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both...
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key glioma patient populations...
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver that commonly arises from underlying liver cirrhosis. Nexavar (Bayer HealthCare...
Hormonal therapies have dominated the treatment of prostate cancer for the past decade. Zytiga (Janssen, generics) and Xtandi (Medivation / Astellas...
The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—...
Market Outlook Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN
Building on the success of Bristol-Myers Squibb / Ono Pharmaceutical’s PD-1 inhibitor Opdivo in the recurrent renal cell carcinoma setting, comb...
Coming Soon – November 2019 Although the malignant melanoma market has become increasingly crowded, an evolving trend of combining drug classes...
MARKET OUTLOOK The lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (...
Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers...
The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care for ovarian cancer; however,...
Market Outlook The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the...
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into...
The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies i...
MARKET OUTLOOK Pancreatic cancer is a life-threatening disease with a survival rate of less than 10% and with no improvements in the last 40 years...
DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key breast cancer patient popu...
Non-Small-Cell Lung Cancer | Current Treatment | Detailed, Expanded Analysis Physician Insights (US)
MARKET OUTLOOK The current treatment algorithm for NSCLC is dominated by targeted branded therapies, reflecting its biomarker-driven treatment...
Get content updates to your inbox
Subscribe